[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oligospermia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oligospermia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,78,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100503974","hyperbaric-oxygen-therapy-for-men-suffering-from-infertility-due-to-oligospermia-100503974",false,"NCT05842239","Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia.","Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia: a Pilot Study","Inclusion Criteria:\n\n1. Age above 21 years\n2. At least two sperm examination showing oligospermia (\\\u003C15·106 sperm\u002FmL)\n3. Diagnosis of idiopathic oligospermia.\n4. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Active malignancy\n3. Previous treatment with chemotherapy and\u002For radiation therapy\n4. Substance use at baseline\n5. Severe or unstable physical disorders or major cognitive deficits at baseline\n6. HBOT for any reason prior to study enrolment\n7. Chest pathology incompatible with pressure changes (including moderate to severe asthma)\n8. Ear or Sinus pathology incompatible with pressure changes\n9. Chronic disease like diabetes mellitus, ischemic heart disease etc.\n10. Active smoking",true,"MALE","21 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","Infertility in a couple is defined as the inability to achieve conception despite one year of frequent, unprotected intercourse. Infertility affects approximately 12% of couples attempting to conceive. The goal of this study is to explore the potential beneficial effect of HBOT on sperm count of infertile male due to oligospermia.",[27],"Oligospermia","RECRUITING","2026-04-19",{"date":31,"type":32},"2026-04-22","ACTUAL",{"date":34,"type":32},"2024-01-20",{"date":36,"type":21},"2030-12-01",{"name":38,"class":39},"Assaf-Harofeh Medical Center","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100620444","identifying-genome-variants-in-non-obstructive-azoospermia-noa-or-primary-ovarian-insufficiency-poi-100620444","NCT07357701","Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)","Identifying Genome Variants and Evaluating PRDM9 and piRNA Clusters as Candidates for Infertility in a Cohort of Individuals With Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Adult male or female, of reproductive age\n4. Clinical diagnosis of NOA, oligospermia, or POI.\n5. In good general health with no medical history suspected as the cause of infertility.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of medications that may cause infertility (chemotherapy, etc.)\n2. Pregnant or lactating\n3. Medical history indicating known common cause of infertility such as karyotype anomalies, Y-chromosome microdeletions, known monogenic causes, or other medical history affecting gamete production (i.e. injuries, surgical operations, infections, radiation, or chemotherapy).","ALL","18 Years","100 Years",{"count":52,"type":21},500,"OBSERVATIONAL","Background:\n\nInfertility affects 1 in 6 people. Often, the causes of infertility are unknown. Treatments are successful in only about 50% of cases. Infertility caused by non obstructive azoospermia in males and primary ovarian insufficiency in females can have genetic causes. Researchers want to learn more about these genes.\n\nObjective:\n\nTo identify genes that may cause infertility.\n\nEligibility:\n\nAdult men and women with non-obstructive azoospermia (NOA) or primary ovarian insufficiency (POI) of unknown cause.\n\nDesign:\n\nParticipants will provide a saliva sample. A kit will be sent to their home. The kit will contain a collection tube and a cotton swab. They will swirl the swab inside their mouth and then seal it in the tube. They will mail the tube back to the researchers.\n\nMale participants who are having a procedure done to collect tissue from their testes may opt to have leftover tissue provided to study researchers. This tissue would otherwise have been discarded. No new procedures will be performed just for this study.\n\nData may be collected from participants medical records.",[56,57,27],"Primary Ovarian Insufficiency","Azoospermia",[59,60,61,62,63,64,65,56,66],"NOA","POI","Premature Ovarian Insufficiency","oligospermia","azoospermia","diminished ovarian reserve","nonobstructive azoospermia","Infertility","2026-03-13",{"date":69,"type":32},"2026-03-16",{"date":71,"type":32},"2026-03-11",{"date":73,"type":21},"2031-01-01",{"name":75,"class":76},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100536067","phase-4-efficacy-and-safety-study-of-products-based-on-tribulus-terrestris-l-in-men-with-oligospermia-100536067","NCT06260007","Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia","Inclusion Criteria:\n\n1. \\- Male;\n2. \\- Ages 25 and 60;\n3. \\- Diagnosis of oligospermia;\n4. \\- With sexual partner;\n5. \\- Indication of drug treatment with steroid hormones, precursors or analogues.\n\nExclusion Criteria:\n\n1. \\- Severe oligospermia\n2. \\- Anatomical change\n3. \\- Previous treatment for oligospermia or concomitant treatment with steroid, anabolic, hormonal precursors such as testosterone or analogues;\n4. \\- BMI 35;\n5. \\- Participant who presents liver enzyme and creatinine values above the upper limit of normality;\n6. \\- History of testicular cancer, or prostate cancer or any other condition that carries risks in this case increased testosterone;\n7. \\- Hypersensitivity to any ingredient present in the formulation;\n8. \\- Any criteria or clinical history that, in the investigator's opinion, could compromise the well-being and participant safety;\n9. \\- Proven infertility of the partner;\n10. \\- History of genetic disorder;\n11. \\- History of psychiatric disorder, serious or decompensated illness or any situation that, Investigator's discretion, puts the participant's safety at risk;\n12. \\- Active cancer at the discretion of the Investigator;\n13. \\- Participants with pregnant and breastfeeding partners;\n14. \\- Cycling and horse riding more than 3 hours per week;\n15. \\- Alcoholism characterized by the inability to control alcohol consumption according to WHO \"drinker excessive, whose dependence on alcohol is accompanied by mental, health and physics, relationships with others and social and economic behavior\". Source: https:\u002F\u002Fwww.cancer.gov\u002Fpublications\u002Fdictionaries\u002Fcancerterms\u002Fdef\u002Falcoholism;\n16. \\- Smoking greater than half a pack per day or equivalent.","25 Years","60 Years",{"count":87,"type":21},204,[89],"PHASE4","Efficacy and Safety of Products Based on Tribulus terrestris, L. in Men with Oligospermia. It is expected that the benefits of investigational products outweigh the risks that will be mitigated or carefully managed by the study team.",[27],"2025-04-03",{"date":94,"type":32},"2025-04-06",{"date":96,"type":32},"2024-07-12",{"date":98,"type":21},"2026-08-17",{"name":100,"class":101},"Herbarium Laboratorio Botanico Ltda","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":40},"100582941","phase-1-study-of-tolerability-safety-pharmacokinetics-pharmacodynamics-and-preliminary-efficacy-of-the-medicinal-product-medireg-100582941","NCT06869863","Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg®","Open Single-center Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg® (Human Mesenchymal Stromal Cell Secretome), Lyophilizate for Preparation of Solution for Injection in Patients with Severe Spermatogenesis Disorders","MARS","Inclusion Criteria:\n\n* 1\\. Male patients aged 21-60 years at the time of inclusion in the study. 2. Persistent severe disorders of spermatogenesis, manifested as severe oligoasthenoteratozoospermia (OAT)\\*, non-obstructive azoospermia, high sperm DNA fragmentation (30% or more), including those caused by secretory infertility according to dynamic control of spermogram (at least 12 months from the moment of inclusion in the study).\n\n  * \"Persistent severe OAT\" should be considered as disorders when sperm concentration \\\u003C5 million\u002FmL, progressively motile sperm \\\u003C13% and\u002For total number of progressively motile sperm in the ejaculate (PMPM) \\\u003C5 million, with the proportion of normal sperm \\\u003C1% according to the dynamic control of spermogram (at least 12 months from the moment of inclusion in the study).\n\n    3\\. inability to conceive against the background of \"severe forms\" of male infertility, not amenable to treatment, including assisted reproductive technologies, within 12 months from the moment of diagnosis or refusal to use assisted reproductive technologies.\n\n    4\\. Voluntarily signed Informed consent by the patient to participate in the clinical trial.\n\n    5\\. Willingness of patients and their sexual partners to use reliable contraceptive methods (combination of at least 2 methods, including 1 barrier method, e.g., use of spermicide and condom) from the time of signing the informed consent until at least 1 month after completion of study participation.\n\n    6\\. Patient willingness to follow all the requirements of the Protocol.\n\nExclusion Criteria:\n\n* 1\\. Age younger than 21 and older than 60 years at the time of inclusion in the study.\n\n  2\\. developmental anomalies of the genitourinary system (according to bladder and kidney ultrasound).\n\n  3\\. surgical interventions on genitourinary organs in the history, except for surgical interventions associated with assisted reproductive technologies. 4.\n\n  4\\. Systemic diseases requiring administration of corticosteroids, cytostatics, radiation therapy.\n\n  5\\. Inflammatory diseases of the urinary and\u002For reproductive system. 6. Infectious diseases (including STDs) of the urinary and\u002For reproductive system.\n\n  7\\. Hereditary factors of infertility: (Klinefelter syndrome (all variants), autosomal abnormalities (all variants), carrying the cystic fibrosis gene (all variants), presence of Y-chromosome microdeletions (all AZF variants), autosomal defects with severe phenotypic abnormalities and infertility (Prader-Willi, Bardet-Biedl, Noonan syndromes, myotonic dystrophy, dominant polycystic kidney disease, 5-alpha-reductase enzyme deficiency, etc.). д.).\n\n  8\\. Obstructive azoospermia by history or established by screening examination. 9. Positive test for HIV, hepatitis B and C, syphilis. 10. Severe liver failure or active liver disease (transaminase activity exceeding 5 times the upper limit of the local laboratory norm).\n\n  11\\. Renal dysfunction with serum creatinine levels exceeding 120 µmol\u002FL. 12. Cardiovascular diseases in the history within 6 months before inclusion in the study, such as myocardial infarction, angina pectoris, severe ventricular arrhythmia, heart failure (NYHA class II-IV).\n\n  13\\. Neurologic (Parkinson's disease) and\u002For psychiatric illnesses with a history or established by screening examination.\n\n  14\\. Cancer with a history of cancer or as determined by screening examination (as determined by OBP and renal ultrasound, bladder ultrasound, prostate TRUS).\n\n  15\\. Hypersensitivity to any of the components of the study drug in the history. 16. Mental illness, severe cognitive impairment, need to take tranquilizers, neuroleptics and\u002For antidepressants during this study.\n\n  17\\. Severe somatic illnesses that, in the opinion of the investigator, may affect the patient's safety and ability to comply with the Protocol.\n\n  18\\. A history of drug dependence. 19. Positive urinalysis for psychotropic and narcotic drugs, psychoactive medications.\n\n  20\\. Intake of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 1⁄2 liter of beer, 200 ml of wine, or 50 ml of alcohol) or a history of alcoholism.\n\n  21\\. Detection of alcohol vapor in breath 22. Participation in another clinical trial currently or in the previous 30 days prior to the screening visit.\n\n  23\\. Patient's inability to understand or comply with study procedures or patient's refusal to cooperate with a particular investigator",{"count":111,"type":21},80,[113,114],"PHASE1","PHASE2","The study is open to patients with severe forms of male infertility (non-obstructive disorders of spermatogenesis, including azoospermia).\n\nThe Phase I\u002FII clinical trial is being conducted at the Lomonosov Moscow State University and is aimed at studying the efficacy and safety of the innovative drug \"MediReg® (Human Mesenchymal Stromal Cell Secretome)\", lyophilizate for preparation of solution for injection, 1.0 ml\u002Fdose for treatment of male infertility. The study was approved by the Ministry of Health of the Russian Federation. The study is planned to include men aged 21 to 60 years with severe spermatogenesis disorders manifested as severe oligoasthenoteratozoospermia (OAT), non-obstructive azoospermia, high sperm DNA fragmentation (30% and more) and faced with the inability to conceive, including with the help of assisted reproductive technologies within 12 months from the date of diagnosis The aim of the therapy is to improve the spermogram indicators in order to increase the chances of successful use of assisted reproductive technologies.\n\nThe drug is injected once under the protein sheath of both testicles. Observation in 1 week after the drug administration is carried out in hospital. Follow-up is performed by outpatient visits to the research center.\n\nThe clinical trial is planned to enroll at least 80 adult patients aged 21 to 60 years with severe spermatogenesis disorders The study will include 3 periods:Screening Period - Day -15...0.\n\n, Period of study drug administration and inpatient follow-up - Day 1 through Day 7., Follow-up period - through Day 90.\n\nThe total duration of participation in the study, including the screening period and the follow-up period, will not exceed 119 days. After the end of the study period, the study will be followed up for 1 year to record delayed adverse events.",[117,118,27,119],"Azoospermia, Nonobstructive","Teratospermia","Men Infertility",[121,63],"men infertility","2025-03-05",{"date":124,"type":32},"2025-03-11",{"date":126,"type":32},"2024-11-26",{"date":128,"type":21},"2025-12",{"name":130,"class":131},"Lomonosov Moscow State University Medical Research and Educational Center","OTHER"]